Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 19:9:785719.
doi: 10.3389/fmed.2022.785719. eCollection 2022.

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study

Yannick Degboé  1 , Richard Koch  1 , Laurent Zabraniecki  1 , Bénédicte Jamard  1 , Guillaume Couture  1 , Jean Bernard Ruidavets  2 , Jean Ferrieres  3 , Adeline Ruyssen-Witrand  1 , Arnaud Constantin  1
Affiliations

Increased Cardiovascular Risk in Psoriatic Arthritis: Results From a Case-Control Monocentric Study

Yannick Degboé et al. Front Med (Lausanne). .

Abstract

Background: Psoriatic arthritis (PsA) is associated with increased cardiovascular morbidity and mortality. The aims of our real-life study were to compare the prevalence of cardiovascular risk factors (CVRFs) and cardiovascular events (CVEs) among patients with PsA with a control population, to evaluate the impact of correcting factors in equations that assess cardiovascular risk (CVR) in PsA, and to determine the percentage of patients who reach the LDLc target as indicated by the European guidelines.

Methods: In this observational cross-sectional monocentric case-control study, we used a standardized procedure to systematically assess patients with PsA aged 25-85 years who met the Classification for Psoriatic Arthritis (CASPAR) criteria. Controls were extracted from the MOnitoring NAtionaL du rISque Artériel (MONALISA) study. We compared the prevalence of CVRFs, CVEs, the CVR, and the percentage of patients reaching recommended LDLc target in both populations. The CVR was first assessed using SCORE and QRISK2 equations. Then, the SCORE equation was corrected by applying a 1.5 multiplication factor, as recommended by EULAR for rheumatoid arthritis (SCORE-PsA), and the QRISK2 was corrected using the "rheumatoid arthritis" item (QRISK2-PsA).

Results: A total of 207 PsA and 414 controls were included. CVRFs and CVEs were more frequent in the PsA group. After controlling for age and gender, atherothrombotic disease was increased in the PsA population (SCORE p = 0.002, QRISK2 p = 0.001). Using the SCORE-PsA increased the percentage of patients with a high or very high CVR from 39.3 to 45.3% in the PsA group. Similarly, using the QRISK2-PsA increased the percentage of patients with a CVR ≥ 10% from 44.9 to 53.2%. The percentages of patients with PsA with high LDLc in the high and very high CVR groups were not significantly different from controls, despite a trend in favor of patients with PsA. Of the 83 PsA with a QRISK2 ≥ 10%, only 22.9% were treated with statin vs. 35.8% of the 134 controls. The QRISK2-PsA score did not alter these results.

Conclusion: In real-life, patients with PsA have a higher prevalence of CVRFs, as well as a higher prevalence of CVEs compared to the general population. The CVR is higher in the PsA population than in the controls either using the SCORE and QRISK2 equations or using the corrected SCORE- PsA and QRISK2-PsA equations.

Keywords: cardiovascular events; cardiovascular risk; dyslipidaemia; psoriatic arthritis; statins.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Stolwijk C, van Onna M, Boonen A, van Tubergen A. The global prevalence of spondyloarthritis: a systematic review and meta-regression analysis. Arthritis Care Res (Hoboken). (2015). [Epub ahead of print]. 10.1002/acr.22831 - DOI - PubMed
    1. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. European guidelines on cardiovascular disease prevention in clinical practice: the sixth joint task force of the European society of cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European association for cardiovascular prevention & rehabilitation (EACPR). Eur Heart J. (2016) 37:2315–81. 10.1093/eurheartj/ehw106 - DOI - PMC - PubMed
    1. Turesson C. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheumat Dis. (2004) 63:952–5. 10.1136/ard.2003.018101 - DOI - PMC - PubMed
    1. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. (2015) 74:326–32. 10.1136/annrheumdis-2014-205675 - DOI - PMC - PubMed
    1. Gladman DD, Ang M, Su L, Tom BDM, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheumat Dis. (2009) 68:1131–5. 10.1136/ard.2008.094839 - DOI - PubMed